Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Rocket pharmaceuticals - What They Never Told You

Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) rose sharply in pre-market trading after the company disclosed that the FDA has lifted the clinical hold on the pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease.

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a firm focused on developing cardiovascular gene therapy, announced a strategic corporate reorganization to extend its runway.

Gene therapy may slow progression of a life-threatening cardiac ailment

Gene therapy may slow progression of a life-threatening cardiac ailment

The investigational treatment targets the loss of function of a gene implicated in many cases of ARVC, plakophilin-2 (PKP2). Read further on Dynamite News:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Betting on Rocket Pharmaceuticals (RCKT)? Check the Options Flow Data First.

Although Rocket Pharmaceuticals lived up to its name on Wednesday due to an encouraging clinical trial development, the big dogs have some questions about RCKT stock.

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

Analyst Ratings for Rocket Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Rocket Pharmaceuticals (NASDAQ:RCKT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Organisations

PayPal Holdings

Canaccord Genuity

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play